File(s) under permanent embargo
Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief
journal contributionposted on 2022-11-24, 03:07 authored by Oliver Massey, Cenk SuphiogluCenk Suphioglu
Interleukin 5 (IL-5) is a major cytokine responsible for eosinophil proliferation, migration and degranulation. Eosinophils play a considerable role in the manifestation of type 2 asthma, and therefore this makes IL-5 a unique and clinically important target for therapeutic intervention. Due to the critical role that IL-5 plays in all areas of eosinophil activity, it has been identified and targeted by three therapeutics, Mepolizumab, Benralizumab and Reslizumab. This review describes the IL-5 pathway and presents the clinical trial history of the three IL-5 inhibitors, to provide insight into the role of IL-5 in clinical asthma presentation. Additionally, this review aims to foster further investigation into the IL-5 pathway by describing current novel therapeutic discovery strategies with monoclonal antibodies.
JournalInternational Journal of Molecular Sciences
Publication classificationC1 Refereed article in a scholarly journal
ALPHA MONOCLONAL-ANTIBODYasthmaBenralizumabBENRALIZUMABBiochemistry & Molecular BiologyChemistryChemistry, MultidisciplinaryDOUBLE-BLINDeosinophilic inflammationHYPEREOSINOPHILIC SYNDROMEIL-5 RECEPTOR-ALPHAimmunotherapyInterleukin-5Life Sciences & BiomedicineMepolizumabMEPOLIZUMABOPEN-LABELPhysical SciencesPLACEBOQUALITY-OF-LIFEReslizumabScience & TechnologySEVERE EOSINOPHILIC ASTHMAAnti-Asthmatic AgentsAntibodies, MonoclonalAsthmaEosinophilsHumansLeukocyte CountClinical ResearchLungClinical Trials and Supportive ActivitiesBiotechnologyRespiratorySchool of Life and Environmental SciencesInstitute for Innovation in Mental and Physical Health and Clinical TranslationFaculty of Science Engineering and Built EnvironmentChemical Sciences not elsewhere classifiedGeneticsBiological Sciences not elsewhere classified